EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry

Kevin O Lillehei, Steven N Kalkanis, Linda M Liau, Dellann Elliott Mydland, Jeffrey Olson, Nina A Paleologos, Timothy Ryken, Tania Johnson, Evan Scullin

CNS Oncology · 30.04.2018 · 7 (2)

DOI: 10.2217/cns-2017-0036 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CNS Oncology, online erschienen am 05.12.2017. Verfasst von Kevin O Lillehei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University of Colorado School of Medicine, Denver, CO, 80045, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Arbor Pharmaceuticals, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBiomarkers, TumorCarmustineCentral Nervous System NeoplasmsDecanoic AcidsDrug ImplantsFollow-Up StudiesHumansPolyestersProspective StudiesRegistriesResearch DesignUnited States

Stichwörter der Autor:innen

BCNU waferschemotherapyglioblastomahigh-grade gliomamultimodalitypatterns of carestudy protocol

Substanzen

Antineoplastic AgentsBiomarkers, TumorDecanoic AcidsDrug ImplantsPolyesterscarmustine, poliferprosan 20 drug combinationCarmustine

Autor:innen und Institutionen

  • Department of Neurosurgery, University of Colorado School of Medicine, Denver, CO, 80045, USA.
  • Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, 48202, USA.
  • Department of Neurosurgery, David Geffen School of Medicine, UCLA, Los Angeles, 90095, CA, USA.
  • EndBrainCancer Initiative, Redmond, WA, 98052, USA.
  • Department of Neurosurgery, Emory University, Atlanta, GA, 30322, USA.
  • Department of Neurology, Advocate Healthcare, Chicago, IL, 60515, USA.

Förderung

  • NCI NIH HHS
  • Arbor Pharmaceuticals, LLC

Zitieren

APA

Lillehei, K. O., Kalkanis, S. N., Liau, L. M., Mydland, D. E., Olson, J., Paleologos, N. A., Ryken, T., Johnson, T., & Scullin, E. (2018). Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry. CNS Oncology, 7(2). https://doi.org/10.2217/cns-2017-0036

Vancouver

Lillehei KO, Kalkanis SN, Liau LM, Mydland DE, Olson J, Paleologos NA, et al. Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry. CNS Oncology. 2018;7(2). doi:10.2217/cns-2017-0036

BibTeX
@article{Lillehei2018,
  author = {Lillehei, Kevin O and Kalkanis, Steven N and Liau, Linda M and Mydland, Dellann Elliott and Olson, Jeffrey and Paleologos, Nina A and Ryken, Timothy and Johnson, Tania and Scullin, Evan},
  title = {Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry},
  journal = {CNS Oncology},
  year = {2018},
  volume = {7},
  number = {2},
  doi = {10.2217/cns-2017-0036}
}
Kostenlos starten →